Development of potential iron chelators for the treatment of Friedreich's ataxia: Ligands that mobilize mitochondrial iron

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1536, Issue 2-3, 2001, Pages 133-140

  Richardson, D R ^a   Mouralian, C ^b   Ponka, P ^b   Becker, E ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Chelator; Desferrioxamine; Friedreich's ataxia; Iron; Iron overload disease; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

2 FUROYLCARBOXALDEHYDE ISONICOTINOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE 3 BROMOBENZOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE 4 HYDROXYBENZOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE ISONICOTINOYL HYDRAZONE; 2 PYRIDYLCARBOXALDEHYDE THIOPHENECARBOXYL HYDRAZONE; 2 PYTIDYLCARBOXALDEHYDE 4 AMINOBENZOYL HYDRAZONE; CHELATING AGENT; DEFEROXAMINE; IRON 59; LIGAND; PHENIPRAZINE; SUCCINYLACETONE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG STRUCTURE; FRIEDREICH ATAXIA; HEME SYNTHESIS; INCUBATION TIME; IRON CHELATION; IRON KINETICS; IRON OVERLOAD; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETICULOCYTE;

ANIMALS; DRUG DESIGN; FRIEDREICH ATAXIA; IRON; IRON CHELATING AGENTS; IRON RADIOISOTOPES; ISONIAZID; LIGANDS; MICE; MITOCHONDRIA; MOLECULAR STRUCTURE; PHENYLHYDRAZINES; PYRIDOXAL; RETICULOCYTES;

ANIMALIA; ATAXIA; MAMMALIA;

EID: 0035978474     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(01)00041-2     Document Type: Article

References (40)

1. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion
2. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes
3. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin
4. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin
5. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in the mitochondrion
6. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue
7. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis
8. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia
9. The yeast frataxin homologue mediates mitochondrial iron efflux
10. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia
11. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia
12. Cardiac iron deposits in Friedreich's ataxia
13. Pathology of the heart in Friedreich's ataxia
14. Erythrocyte protoporphyrin levels in patients with Friedreich's and other ataxias
15. Evidence for mitochondrial iron overload in patients with Friedreich's ataxia
16. Iron metabolism in K562 erythroleukemic cells
17. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell
18. Mobilisation of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent
19. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone
20. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents
21. Effective iron chelation following oral administration of an isoniazid pyridoxal hydrazone
22. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone
23. Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration
24. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
25. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues
26. The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone
27. Succinylacetone, a potent inhibitor of heme biosynthesis: Effect on cell growth, heme content and delta-aminolevulinic acid dehydratase activity of malignant murine erythroleukemia cells
28. Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor of heme synthesis
29. The effects of inhibition of heme synthesis on the intracellular localisation of iron in rat reticulocytes
30. Iron distribution in Belgrade rat reticulocytes after inhibition of heme synthesis with succinylacetone
31. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism
32. Tissue-specific regulation of iron metabolism and heme synthesis: Distinct control mechanisms in erythroid cells
33. Chelator-mediated iron efflux from reticulocytes
34. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate
35. Effect of pyridoxal isonicotinoyl hydrazone (PIH) and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes
36. 59Fe
37. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents
38. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone
39. Iron-chelating therapy and the treatment of thalassemia
40. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study